The US declares a public health emergency over the coronavirus outbreak; the FDA approves the first treatment for peanut allergy in children, sold as Palforzia; the Trump administration rejects California's healthcare tax on managed care organizations.
Last Friday, the Trump administration declared a public health emergency due to the coronavirus outbreak, with further action that includes barring entry to the United States of foreign nationals who have traveled to China, according to Reuters. HHS Secretary Alex Azar held a media briefing at the White House on the announcement, which, as of yesterday, will subject US citizens to a mandatory 14-day quarantine if they have traveled to China’s Hubei Province within the last 14 days.
According to an FDA press release on Friday, the agency approved the first drug for treatment of peanut allergy in children. Sold as Palforzia (peanut [Arachis hypogea] allergen powder-dnfp), the treatment works by mitigating allergic reactions, including anaphylaxis, that may occur with accidental exposure to peanuts. The treatment is a powder that is manufactured from peanuts and administered in 3 phases: initial dose escalation, up-dosing, and maintenance. Along with the approval, the FDA is requiring a Risk Evaluation and Mitigation Strategy (REMS) for Palforzia, and patients must be enrolled in the REMS program to receive the drug.
The Trump administration said it will not allow California to collect a healthcare tax on managed care organizations, a move linked to the loss of $2 billion a year for the state in low-income benefits, according to the Associated Press. The decision will affect California’s fiscal year beginning on July 1, 2021, as the state did not plan to receive this income this year. “Consistent with the federal government’s prior approvals of similar financing waivers, we believe and expect that we can reach an agreement that allows this type of financing to continue,” said H.D. Palmer, spokesman for the California Department of Finance.
Urticaria Diagnosis Challenged by Overlapping Pruritic Skin Conditions
April 23rd 2025Urticaria is complicated to diagnose by its symptomatic overlap with other skin conditions and the frequent misclassification in literature of distinct pathologies like vasculitic urticaria and bullous pemphigus.
Read More
New Research Challenges Assumptions About Hospital-Physician Integration, Medicare Patient Mix
April 22nd 2025On this episode of Managed Care Cast, Brady Post, PhD, lead author of a study published in the April 2025 issue of The American Journal of Managed Care®, challenges the claim that hospital-employed physicians serve a more complex patient mix.
Listen
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
ACOs’ Focus on Rooting Out Fraud Aligns With CMS Vision Under Oz
April 23rd 2025Accountable care organizations (ACOs) are increasingly playing the role of data sleuths as they identify and report trends of anomalous billing in hopes of salvaging their shared savings. This mission dovetails with that of CMS, which under the new administration plans to prioritize rooting out fraud, waste, and abuse.
Read More
Urticaria Diagnosis Challenged by Overlapping Pruritic Skin Conditions
April 23rd 2025Urticaria is complicated to diagnose by its symptomatic overlap with other skin conditions and the frequent misclassification in literature of distinct pathologies like vasculitic urticaria and bullous pemphigus.
Read More
New Research Challenges Assumptions About Hospital-Physician Integration, Medicare Patient Mix
April 22nd 2025On this episode of Managed Care Cast, Brady Post, PhD, lead author of a study published in the April 2025 issue of The American Journal of Managed Care®, challenges the claim that hospital-employed physicians serve a more complex patient mix.
Listen
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
ACOs’ Focus on Rooting Out Fraud Aligns With CMS Vision Under Oz
April 23rd 2025Accountable care organizations (ACOs) are increasingly playing the role of data sleuths as they identify and report trends of anomalous billing in hopes of salvaging their shared savings. This mission dovetails with that of CMS, which under the new administration plans to prioritize rooting out fraud, waste, and abuse.
Read More
2 Commerce Drive
Cranbury, NJ 08512